Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A new type of targeted immunotherapy drug, tarlatamab shrank tumors in about 1 in 3 people with small-cell lung cancer.
Two new clinical trials compare Retevmo (selpercatinib) with other standard treatments for tumors with changes in the RET gene.
As a result of the investment in cancer research, NCI was in a strong position to make key early advances in the fight against HIV/AIDS.
The Invitae test analyzes a person’s blood sample for changes in 47 genes that are linked to hereditary forms of cancer.
Early research in animals shows potential against cervical cancer and neuroblastoma.
Dr. W. Kimryn Rathmell of Vanderbilt University Medical Center is a renowned kidney cancer expert.
Stereotactic body radiotherapy (SBRT) appears to be a highly effective option for early-stage kidney cancer.
A study found that physical activity prolonged disease-free survival for people with Stage III colon cancer.
Bertagnolli is committed to making clinical trials faster, more inclusive and more responsive.
Monica Bertagnoli was asked about issues ranging from high drug prices to the opioid crisis to gender-affirming care.
Rosenberg pioneered cancer treatments including tumor-infiltrating lymphocytes and CAR-T therapy.
Artificial intelligence–backed chatbots can provide accurate info about cancer—but also include errors and omissions, two studies show.
New immunotherapies improve outcomes, but access to care and clinical trials for many still lags, notes an AACR cancer report. [VIDEO]
A study in mice found that engineered "bacterial biosensors” could detect DNA shed by colorectal cancer tumors.
Novel treatment relies on a newer form of CRISPR gene-editing technology called base editing.
Report findings suggest many cancers were not being diagnosed in a timely manner during the early part of the pandemic.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.